Last reviewed · How we verify

Cipro (Ciprofloxacin)

Alk Abello · FDA-approved approved Small molecule Quality 68/100

Ciprofloxacin interferes with bacterial DNA gyrase, inhibiting DNA synthesis.

Ciprofloxacin ophthalmic solution is a fluoroquinolone antibiotic indicated for corneal ulcers and conjunctivitis caused by susceptible organisms. Systemic absorption is minimal with maximum plasma concentrations less than 5 ng/mL following topical ocular administration. Contraindications include hypersensitivity to ciprofloxacin or other quinolones. Drug interactions are primarily associated with systemic quinolone administration affecting theophylline, warfarin, cyclosporine, and caffeine metabolism.

At a glance

Generic nameCiprofloxacin
SponsorAlk Abello
Drug classFluoroquinolone
TargetDNA gyrase
ModalitySmall molecule
PhaseFDA-approved
First approval1987

Mechanism of action

Ciprofloxacin is a fluoroquinolone antibiotic that exerts bactericidal activity through interference with DNA gyrase, an essential enzyme required for bacterial DNA synthesis. This mechanism of action results in inhibition of bacterial DNA replication and transcription, leading to cell death. The drug demonstrates in vitro activity against a wide range of gram-negative and gram-positive organisms.

Approved indications

Common side effects

Drug interactions

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: